ACXP

Business Context and Reporting Period

Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company developing a new class of small molecule antibiotics targeting Gram-positive bacteria. The company's lead candidate, ibezapolstat, is a DNA polymerase IIIC inhibitor in Phase 3 development for the treatment of Clostridioides difficile infection (CDI). The company also has an early-stage pipeline candidate, ACX-375C, targeting MRSA and VRE. This summary covers the fiscal year ended December 31, 2024.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt. As of December 31, 2024, current liabilities totaled $3.2 million, primarily accounts payable and accrued expenses. The company reported a net decrease in cash of $3.8 million for the year.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 3% ($0.5 million) compared to 2023, driven by a decrease in Research and Development (R&D) expenses.
• R&D Expenses: Decreased from $6.0 million in 2023 to $5.4 million in 2024. This was primarily due to a $1.6 million reduction in consulting fees, partially offset by a $1.0 million increase in manufacturing costs.
• G&A Expenses: Increased slightly from $8.5 million to $8.7 million, driven by higher legal and professional fees, offset by lower share-based compensation.
• Cash Position: Cash reserves declined significantly from $7.5 million to $3.7 million due to operating cash outflows of $10.4 million, partially funded by $6.6 million in financing activities (primarily At-the-Market offerings).

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Phase 3 Readiness: Following a successful End-of-Phase 2 meeting with the FDA in April 2024, the company confirmed readiness to advance ibezapolstat into international Phase 3 clinical trials. Positive feedback was received from the FDA regarding the Chemistry, Manufacturing, and Controls (CMC) plan in December 2024.
• Regulatory Status: Ibezapolstat holds FDA Fast Track and Qualified Infectious Disease Product (QIDP) designations. The company received positive regulatory guidance from the European Medicines Agency (EMA) in January 2025.
• Capital Needs: Management stated that existing cash resources ($3.7 million as of year-end) are not sufficient to fund anticipated operations for at least 12 months from the issuance of the financial statements. The company expects to continue incurring net losses until commercialization.

Risks and Contingencies

• Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows.
• Financing Requirements: The company must raise additional capital to fund Phase 3 trials. Failure to do so could force delays, reductions, or termination of development programs.
• Nasdaq Compliance: On February 24, 2025, the company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. The company has a 180-day grace period to regain compliance.
• Recent Dilution: Subsequent to year-end, the company completed two registered direct offerings (January and March 2025) raising approximately $3.6 million in aggregate gross proceeds, involving significant issuance of common stock and warrants.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.7 million cash balance against the projected costs of initiating and conducting international Phase 3 trials.
• Financing Terms: Review the terms of the January and March 2025 registered direct offerings, specifically the exercise prices of the warrants issued ($0.90 and $0.40) and the potential for further dilution.
• Nasdaq Status: Monitor the company's ability to regain compliance with Nasdaq's minimum bid price requirement by August 25, 2025, to avoid delisting.
• Phase 3 Timeline: Confirm the start date and enrollment progress of the Phase 3 clinical trials for ibezapolstat.
• Going Concern Mitigation: Assess the likelihood of securing additional funding given the current market conditions and the company's recent equity raises at discounted prices.